Lb Pharmaceuticals Inc (LBRX) Stock Price & Analysis
Lb Pharmaceuticals Inc (LBRX) fell 0.44% to USD 29.27 as of June 10, 2026 at 04:04 UTC, according to Nexqual real-time market data.
LBRX last closed at USD 29.4; the session ranged USD 29–30.36 on volume of 362,150 shares. Market capitalization is $839.37M, with a 52-week range of USD 13.36–33.47 (NGM). Source: Nexqual, June 10, 2026 at 04:04 UTC.
Key Statistics (as of June 10, 2026 at 04:04 UTC)
| Price | USD 29.27 |
|---|---|
| Change | ▼ 0.44% (down) |
| Previous Close | USD 29.4 |
| Open | USD 29.54 |
| Day Range | USD 29 – 30.36 |
| 52-Week Range | USD 13.36 – 33.47 |
| Volume | 362,150 shares |
| Market Cap | $839.37M |
| Exchange | NGM |
Technical Analysis (LBRX)
Nexqual's technical model rates LBRX "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 04:04 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.59 (neutral) |
| vs SMA50 | Above (USD 28.86) |
| MACD | -0.3 (negative) |
Analyst Ratings (LBRX)
Wall Street analysts rate LBRX "Strong Buy" based on 6 analysts, with a mean price target of USD 45 (range USD 34–78), per Nexqual as of June 10, 2026 at 04:04 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 45 |
| High Target | USD 78 |
| Low Target | USD 34 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (LBRX)
| Next Earnings Date | 2026-05-15 |
|---|---|
| EPS Estimate | USD -0.81 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.45 vs est -0.32 ▼ miss |
| 2025-09-30 | USD -0.61 vs est -0.28 ▼ miss |
Source: Nexqual, June 10, 2026 at 04:04 UTC.
Financials & Fundamentals (LBRX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -19.56% |
| Debt / Equity | 0.92 |
| Current Ratio | 35.68 |
| Total Cash | $365.64M |
| Total Debt | $3.47M |
Source: Nexqual, June 10, 2026 at 04:04 UTC.
Financial Health Score (LBRX)
Nexqual rates Lb Pharmaceuticals Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $366M cash vs $3M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$50M |
| Efficiency | Critical — ROE -20% |
Ownership (LBRX)
| Insider Ownership | +0.27% |
|---|---|
| Institutional Ownership | +106.77% |
| Shares Outstanding | 28.68M |
| Float | 18.10M |
| Short % of Float | +16.85% |
Source: Nexqual, June 10, 2026 at 04:04 UTC.
Leadership (LBRX)
Lb Pharmaceuticals Inc is led by Heather D. Turner Esq. (age 52), CEO & Director, per Nexqual as of June 10, 2026 at 04:04 UTC.
| CEO & Director | Heather D. Turner Esq. (age 52) |
|---|---|
| Chief Operating & Business Officer | Gad Soffer (age 48) |
| Senior Vice President of Finance | Marc L. Panoff (age 55) |
| Senior Vice President of Technical Operations | Richard A. Silva (age 57) |
| Senior Vice President of Regulatory Affairs | James Rawls Pharm.D. |
Major Backers & Investors (LBRX)
Notable institutional backers of Lb Pharmaceuticals Inc include Deep Track Capital, Lp, JPMorgan, RA Capital Management, L.P., according to Nexqual as of June 10, 2026 at 04:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 11.69% |
| JPMorgan | 8.34% |
| RA Capital Management, L.P. | 7.7% |
| TCG Crossover Management, LLC | 6.41% |
| Commodore Capital Lp | 5.23% |
| Caligan Partners, LP | 5.01% |
| Spruce Street Capital LP | 4.8% |
| Trails Edge Capital Partners, LP | 4.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.92% |
Source: Nexqual, June 10, 2026 at 04:04 UTC.
From Lb Pharmaceuticals Inc's Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
- Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MPLT | MapLight Therapeutics, Inc. | USD 29.27 | ▲ 4.5% |
| MAZE | Maze Therapeutics, Inc. | USD 23.93 | ▼ 1.4% |
| EVMN | Evommune, Inc. | USD 20.49 | ▲ 2.86% |
| SION | Sionna Therapeutics, Inc. | USD 33.69 | ▼ 4.75% |
| MBX | MBX Biosciences, Inc. | USD 29.87 | ▼ 1.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:04 UTC. This page is informational and not investment advice.